0000835887-12-000016.txt : 20120322 0000835887-12-000016.hdr.sgml : 20120322 20120322155436 ACCESSION NUMBER: 0000835887-12-000016 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20120316 ITEM INFORMATION: Changes in Registrant's Certifying Accountant FILED AS OF DATE: 20120322 DATE AS OF CHANGE: 20120322 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROGENICS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000835887 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133379479 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23143 FILM NUMBER: 12709328 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9147892800 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 8-K 1 form8_kmarch162012.htm PROGENICS FORM 8-K MARCH 16, 2012 form8_kmarch162012.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) March 16, 2012
 
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
  
000-23143
  
13-3379479
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(IRS Employer
Identification No.)
         
777 Old Saw Mill River Road, Tarrytown, New York
  
10591
(Address of principal executive offices)
  
(Zip Code)
Registrant's telephone number, including area code (914) 789-2800
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 
 
 


Item 4.01.
Changes In Registrant’s Certifying Accountant.
 

 
(a)           On March 16, 2012, Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) dismissed PricewaterhouseCoopers LLP (PwC) as the Company’s independent registered public accounting firm. Progenics’ Audit Committee and the Board of Directors approved the decision.
 
Neither of PwC’s reports on Progenics’ consolidated financial statements for the years 2010 and 2011 contained an adverse opinion or a disclaimer of opinion, or was qualified or modified as to uncertainty, audit scope or accounting principles.
 
During 2010, 2011 and through March 16, 2012, (a) Progenics did not have any disagreements with PwC on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure which, if not resolved to the satisfaction of PwC, would have caused it to make reference to the subject matter of the disagreement(s) in connection with its report(s), and (b) no “reportable events” as defined in Item 304(a)(1)(v) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission occurred.
 
Progenics has requested PwC to furnish the Company with a letter addressed to the SEC stating whether it agrees with the above statements.  A copy of that letter is included in this Report as Exhibit 16.1.
 
(b)           On March 16, 2012, Progenics determined to appoint Ernst & Young LLP (E&Y) to serve as the Company’s independent registered public accounting firm to audit its consolidated financial statements for 2012. Progenics’ Audit Committee and the Board of Directors approved the decision. During 2010, 2011 and through March 16, 2012, neither Progenics nor anyone acting on its behalf consulted with E&Y regarding any matters described in Items 304(a)(2)(i) or (ii) of Regulation S-K.

Exhibit No.            Description

16.1
Letter dated March 16, 2012 from PwC to the SEC.

 
 
 

SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
                               PROGENICS PHARMACEUTICALS, INC.
                               By:  /s/ ROBERT A. MCKINNEY                            
                                     Robert A. McKinney,
                                     Chief Financial Officer and
                                     Senior Vice President, Finance & Operations
 
 
 
Date: March 22, 2012


 
 EX-16.1 2 ex16_1march162012.htm PROGENICS EXHIBIT 16.1 MARCH 16, 2012 ex16_1march162012.htm


 
                                           EXHIBIT 16.1
 

 
March 16, 2012
 
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
 
Commissioners:
 
We have read the statements made by Progenics Pharmaceuticals, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K, as part of the Form 8-K of Progenics Pharmaceuticals, Inc. dated March 16, 2012. We agree with the statements concerning our Firm in such Form 8-K.
 
Very truly yours,
 
/s/ PricewaterhouseCoopers LLP